Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ETCompany ParticipantsAlbert Bourla - Chairman of ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an ...

“MRNA probably is the most utilized vaccine in the history of humanity,” Pfizer CEO Dr. Albert Bourla said Friday, noting that there have been about 1.5 billion mRNA vaccine doses against ...

Pfizer CEO Dr. Albert Bourla speaks to CNN’s Meg Tirrell about pushing past vaccine skepticism to work with the Trump ...